Monacolin K – the first OTC statin or extraordinary dietary supplement? Review article
Article Sidebar
Main Article Content
Abstract
The most common CVD’s risk factor is dyslipidemia and the statins are still the most important antihyperlipidemic agents. This very paper treats efficacy, safety, and role of dietary supplement, statin derivate – monacolin K and its role in modern cardiologic pharmacotherapy.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Śliż D., Mamcarz A., Filipiak K.J. et al.: 3ST-POL trial: standards of statin use in Poland in the context of the European Society of Cardiology guidelines. Pol. Arch. Med. Wewn. 2010; 120(9): 328-33.
3. Śliż D., Filipiak K.J., Naruszewicz M. et al.: Standard of Statin usage in Poland in high risk patients: 3ST-POL study results. Kardiol. Pol. 2013; 73(3): 253-259.
4. Gordon R.Y., Cooperman T., Obermeyer W. et al.: Marked variability of monacolin levels in commercial red yeast rice products: Buyer beware! Arch. Intern. Med. 2010; 170: 1722-1727.
5. Liu J., Zhang J., Shi Y. et al.: Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chinese Medicine 2006; 1: 4.
6. Cheng-Chieh L., Tsai-Chung L., Ming-May L.: Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. European Journal of Endocrinology 2005; 153: 679-686.
7. Halbert S.C., French B., Gordon R.Y.: et al.: Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am. J. Cardiol. 2010; 105(2): 198-204.